J&J Risperdal Pituitary Tumor Risk To Be Evaluated In FDA Claims Study
Executive Summary
FDA's Division of Psychiatry Products and Office of Surveillance & Epidemiology are planning a study to determine if Johnson & Johnson's Risperdal (risperidone) has an increased risk of pituitary adenoma versus other antipsychotics
You may also be interested in...
Adverse Event Analysis Could Leap Forward With New Statistical Techniques
Data mining the FDA Adverse Event Reporting System could take a leap forward as researchers validate a new statistical algorithm and publish results later this year
Clozaril Superior In Phase Two Of CATIE, But Side Effects Remain A Challenge
The superiority of Novartis' Clozaril over second-generation antipsychotics in the second phase of the National Institute of Mental Health's CATIE trial suggests the need to manage the serious side effects of clozapine therapy while expanding its use, study authors argue
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011